Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS patients and can create a substantial social and economic bu…
Sandoz to appeal court ruling to United States Court of Appeals for the Federal CircuitRuling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases Sandoz remains deeply commi…
Sandoz to appeal court ruling to United States Court of Appeals for the Federal CircuitRuling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases Sandoz remains deeply commi…
Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures — number se…
Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulator…
Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1SYMJEPI will help address critical impact of ongoing epinephrine auto-…
Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourt…
Sandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently Collaboration will optimize supply chain by providing real-time inventory reports, plus …
Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1] ADMYRA data reinforces review summarizing 90+ public…
Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segmentsRealignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, …